CASI PHARMACEUTICALS, INC. Stock-Based Compensation
CASI PHARMACEUTICALS, INC. (CASIF) reported Stock-Based Compensation of $2.99 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-05-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-05-15
| Period end | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|
| 2025-12-31 | $2.99M 20-F · filed 2026-05-15 |
| 2024-12-31 | $1.31M 20-F · filed 2026-05-15 |
| 2023-12-31 | $7.22M 20-F · filed 2026-05-15 |
| 2022-12-31 | $7.01M 20-F · filed 2025-03-31 |
| 2021-12-31 | $7.77M 20-F · filed 2024-03-28 |
| 2020-12-31 | $7.82M 20-F · filed 2023-04-26 |